Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Gastroduodenal Artery	NCIT_C150362	[A small artery located in the abdomen that arises from the common, left, or right hepatic artery, and supplies blood to the pylorus of the stomach, the proximal duodenum, and the head of the pancreas.]
NZB	NCIT_C14704
A Kirschbaum, Baylor, 1942-52	NCIT_C14705
L2 Mouse	NCIT_C14706
Multiple Crosses: C57L, DBA/2, C57BL-go, 129/J	NCIT_C14707
YT/Y Mouse	NCIT_C14708
Hermansky-Pudlak Syndrome 1	NCIT_C150367	[An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the HPS1 gene, encoding Hermansky-Pudlak syndrome 1 protein. This sub-type is associated with pulmonary fibrosis.]
Hermansky-Pudlak Syndrome	NCIT_C37261	[A group of autosomal recessive inherited disorders characterized by albinism, bleeding tendency, and lung disorders such as pulmonary fibrosis.]
C57BL/6J, C57BR/cdJ, A/J, BALB/cJ, LG/Ckc, SM/Ckc	NCIT_C14709
Hermansky-Pudlak Syndrome 2	NCIT_C150368	[An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the AP3B1, encoding AP-3 complex subunit beta-1. Immunodeficiency due to neutropenia is a characteristic of this sub-type.]
Hermansky-Pudlak Syndrome 6	NCIT_C150369	[An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the HPS6 gene, encoding Hermansky-Pudlak syndrome 6 protein. Individuals with this type of syndrome, as well as with types 3 or 5, have the mildest symptoms.]
Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352	NCIT_C150363	[A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.]
Therapeutic Estrogen	NCIT_C483	[A class of natural or synthetic hormones that binds to a cytoplasmic receptor and initiates translocation of the hormone-receptor complex to the nucleus of target cells of tissues rich in estrogen receptors, including the endometrium, myometrium, oviduct, vagina, fallopian tube, cervix, brain, liver, placenta, ovarian cells, Leydigs cells, kidney, prostate, pancreas, heart, and skin. (NCI)]
Refractory Urothelial Carcinoma	NCIT_C150364	[Urothelial carcinoma that does not respond to treatment.]
Refractory Urinary System Carcinoma	NCIT_C162719	[Urinary system carcinoma that does not respond to treatment.]
Platinum-Resistant Urothelial Carcinoma	NCIT_C150365	[Urothelial carcinoma that does not respond to platinum-based treatments.]
Percent of Prostate Cores Positive for Carcinoma	NCIT_C150366	[The number of prostate core biopsy samples positive for carcinoma divided by the total number of prostate core samples.]
LLC/Ckc Mouse	NCIT_C14710
HLC/Ckc Mouse	NCIT_C14711
Heterogeneous Stock from A/Sn, BALB/c, CBA/Ca, C57BL/6J, DBA/2, GLF, I/St, 101/H	NCIT_C14712